Kairos Pharma, Ltd. KAPA
We take great care to ensure that the data presented and summarized in this overview for Kairos Pharma, LTD. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in KAPA
Top Purchases
Top Sells
About KAPA
Insider Transactions at KAPA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 01
2025
|
John S Yu CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+0.26%
|
-
|
|
Jan 01
2025
|
Ramachandran Murali VP of Research and Development |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+8.69%
|
-
|
|
Nov 25
2024
|
Ramachandran Murali VP of Research and Development |
BUY
Open market or private purchase
|
Direct |
200
+0.15%
|
$200
$1.59 P/Share
|
|
Nov 22
2024
|
Doug Samuelson Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+3.95%
|
$2,500
$1.5 P/Share
|
|
Nov 20
2024
|
John S Yu CEO and Chairman |
BUY
Open market or private purchase
|
Direct |
4,000
+0.07%
|
$4,000
$1.44 P/Share
|
Last 12 Months Summary
Buy / Acquisition
34.7K
Shares
From
5
Insiders
| Open market or private purchase | 6.7K shares |
|---|---|
| Grant, award, or other acquisition | 28K shares |
Sell / Disposition
0
Shares
From
0
Insiders